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Summary
Objective: This work was undertaken to assess the protective effect of an isoﬂavonoid, calycosin-7-O-b-D-glucopyranoside (CG), isolated from
Astragali radix (AR) on the pathogenesis of osteoarthritis (OA)-like lesion in a rabbit model.
Methods: Nine rabbits underwent an anterior cruciate ligament and menisectomy transection (ACLMT) of the rear knee joints to induce OA-like
lesion. They were randomly divided into three groups (n¼ 6/group): a negative control group treated with 200 ml of 0.5% (v/v) dimethyl sulfoxide
(DMSO), a positive control group treated with 200 ml of 100 mM piroxicam, and a test group treated with 100 mg/500 ml of CG, where the test
agents were administered by injection once a week for 4 weeks starting from the third week. Rabbits were then sacriﬁced to observe the
progression of OA-like lesion. The synovial ﬂuid was analyzed for the amounts of total proteins, glycosaminoglycans (GAG) and prostaglandin
E2 (PGE2). In addition, histopathologic analyses were performed on the OA-like articular cartilage with or without therapeutic treatments.
Results: The total synovial ﬂuid volume (P< 0.05) was most strikingly reduced by the treatment with CG. Moreover, the CG treatment also
signiﬁcantly alleviated the OA-induced accumulation of prostaglandin (PG) (P< 0.001) and total proteins (P< 0.001) in the synovial ﬂuid.
The histopathologic analyses revealed that the CG treatment reduced the severity of the OA-like structural damages in the cartilage. However,
the level of PGE2, a pathologic inﬂammatory molecule, was not diminished by CG or piroxicam.
Conclusion: These results indicate that the isoﬂavonoid CG isolated from AR signiﬁcantly alleviated the pathologic changes in the OA-like
rabbit knee joints. This suggests that CG from AR could be a promising treatment for the therapy of OA.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.





Osteoarthritis (OA) is a chronic and degenerative multi-fac-
torial joint disease characterized by the ﬁbrillation of articu-
lar cartilage, bone remodeling, hypertrophy, inﬂammation of
the synovial membrane, and in some cases sclerosis of
subchondral bone and osteophyte formation1. OA is one
of the most common joint disorders, affecting approximately
14.5% of the total population and nearly 80% of the geriatric
population over the age of 602. Under normal conditions,
the maintenance of joint cartilage is predicated on a delicate
balance between extracellular matrix (ECM) synthesis and
degradation. In particular, hyaluronic acid (HA), an impor-
tant component of the cartilage, is synthesized by the glyco-
syltransferase, accumulated in the ECM, and then interacts
with link proteins and aggrecan. Meanwhile, the cartilage
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Received 15 June 2006; revision accepted 10 February 2007.10matrix degradation is a multi-factorial process involving
the progressive erosion of articular cartilage, prostaglandin
(PG) degradation, disruption of the collagen network and
eventually the functional loss3.
Until now, the conservative treatment for OA is limited to
a few classes of OA drugs such as paracetamol, non-
steroidal anti-inﬂammatory drugs (NSAIDs), injectable
intra-articular corticosteroids, anti-inﬂammatory steroids,
cyclooxygenase (COX) inhibitory drugs and HA. These
OA drugs provide general symptomatic relief, maintain
the mobility and decrease pain and stiffness in the joint4.
However, they also suffer from various side effects in the
gastrointestinal system including nausea, vomiting, diar-
rhea and drowsiness5,6.
Astragali radix (AR) is a dried root of Astragalus mem-
branaceus Bunge (Leguminosae) and has been used for
centuries as an important medicine to reinforce vital en-
ergy, strengthen superﬁcial resistance and promote the
discharge of pus and growth of new tissues. It has also
been established that AR contains various active compo-
nents including astragaloside, formononetin, calycosin,
(3R)7,20-dihydroxy-50,60-dimethoxy-isofalvon-7-O -b-D-gluco-
side, b-sitosterol, palmatic acid, isorhamnetin, quercetin,
kaempferol, polyamine and daucosterol. In particular, ﬂa-
vonoids have been established as one of the most beneﬁcial86
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such as anti-oxidative, immunomodulatory and even
anti-cancer activities7. In a previous study, we showed
that AR had a high inhibitory effect on hyaluronidase
(HAase) activity in vitro and identiﬁed calycosin-7-O -b-D-
glucopyranoside (CG) as an active component of AR re-
sponsible for the effect8. In addition, the AR extracts or
CG treatment was found to signiﬁcantly inhibit matrix deg-
radation caused by recombinant human interleukin-1b (IL-
1b) or HAase in the human articular cartilage explant and
chondrocytes9.
Accordingly, the present study investigated the protective
effect of CG isolated from AR on the pathogenesis of artic-
ular cartilage, including the matrix degradation and inﬂam-
matory responses using an anterior cruciate ligament and
menisectomy transection (ACLMT)-induced rabbit OA
model. The effects of CG on cartilage degradation were
compared with piroxicam (a nonselective COX-2 inhibitor)
as a positive control.
Materials and methods
PREPARATION OF CG
Chemically pure CG was obtained from the Biotechnology
Laboratory at Inha University (Incheon, Korea). Puriﬁed CG
was characterized on the basis of chemical and spectroscopic
evidences including high-performance liquid chromatography
(HPLC), liquid chromatography (LC)emass spectrometry
(MS)/MS, fourier transform-infrared spectroscopy (FTeIR),
and 1H/13C NMR spectra using the National Center for Inter-
University Research facilities9,10. The chemical structure of
CG is shown in Fig. 1. The LCeelectrospray interface
(ESI)eMS spectrum was [MþþH] at 447 m/z, while the
LCeESIeMS/MS spectrum was [MþþH] at 285 m/z for the
molecular formula, C22H22O10.
EXPERIMENTAL ANIMALS
Nine New Zealand white rabbits at adolescent (aged 7
months) and weighing 3.0e3.5 kg (Joong-Ang Experimen-
tal Animal Center, Korea) were used in the experiments.
The animals were individually housed in stainless-steel ca-
ges, maintained under the same environmental conditions
(temperature of 20 0.5C, relative humidity of 55 5%,
with a light/dark period of 12 h) for 2 weeks or more, and
provided with a standard rabbit diet and ﬁltered water ad
libitum throughout the experimental period.
INDUCTION OF OA-LIKE LESION
OA-like lesion was induced in both knees of the rear legs
of the rabbits via an ACLMT as described in a preceding pa-
per11. According to a protocol approved by the Institutional
Fig. 1. Structure of CG isolated from AR.Review Board of Inha University School of Medicine, the
rabbits were anesthetized with ketamine hydrochloride
(Yoo Han Yang Hang, Anyang, Korea) and rompun (Bayer,
Ansan, Korea) (7:3, i.m.) at a concentration of 1 ml/kg body
weight. The fur of the anesthetized rabbits was removed us-
ing a clipper (SM-10, JOAS Electronics, Korea), and the
skin and soft tissue were cut open from the medial portion
to expose the joint. After ﬂexing the knee, the cruciate liga-
ment was severed at the point of attachment to the tibia,
and the anterior horn of the medial meniscus was trans-
ected and removed. After surgery, the joint surface was
washed with sterile saline solution, and the joint capsule
and the skin were closed independently with 4-0 nylon su-
tures. Exercise of rabbits was performed to induce OA-
like lesion in the joints from day 3 after the ACLMT surgery
until the fourth week in a conﬁned space (5 5 m2) for 1 h
each time, two times a day. All rabbits were forced to keep
moving at constant intervals so that an equal quality of OA
models could be produced.
TREATMENT OF CG
The sample injection was started on third week after the
ACLMT surgery once a week for 4 weeks. The nine rabbits
with OA-like lesion were divided into three groups; the OA
model group received 200 ml of a 0.5% dimethyl sulfoxide
(DMSO) saline buffer (negative control), the second group
received 200 ml of piroxicam (100 mM, positive control)
and the third group received 500 ml of CG (100 mg in
a buffer). The concentration of CG (200 mg/ml) was selected
based on our previous results in vitro9. Piroxicam is already
known as a nonselective COX-2 inhibitor, yet it has no
signiﬁcant effect on the matrix synthesis12. The injections
of test reagents into both knee joints (n¼ 6/group) were per-
formed once a week for 4 weeks using a 26G needle. The
concentrations of each treatment were determined based
on a clinical dose and the dose-response data prior to the
experiments (data not shown). Three additional rabbits
that did not undergo surgery but injected with 0.5%
DMSO saline buffer were also used as a normal control.
ASPIRATION OF SYNOVIAL FLUID
Synovial ﬂuid was collected from the animals under anes-
thesia at the following time points: normal condition, and 0,
2 and 4 weeks after the initial injection of each treatment
sample as previously described11. As such, 1 ml of synovial
ﬂuid was aspirated using an 18G needle after injecting
0.5 ml of physiological saline into the joint and ﬂexing the
knee 10 times. The extracted ﬂuid was then diluted in
1 ml of phosphate buffered saline (PBS) and centrifuged
at 13,000 rpm for 15 min to remove the cell and tissue
debris. The supernatants were stored in aliquots at 20 C
until use.
HISTOPATHOLOGICAL EXAMINATIONS
After 28 days of treatment, the rabbits were sacriﬁced and
subjected to the histological assessment for affected medial
condyle of each femur. The tissue was ﬁxed with 10% for-
malin and the calcium was removed from the tissue via
the incubation in 5% nitric acid for 24 h. The tissue sections
were then examined under a microscope after staining with
hematoxylin and eosin, or safranin-O for the detection of PG
loss in the cartilage. The histological evaluation for anti-
degenerative effects was performed using a section in the
middle position of medial condyle that showed most severe
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group)13. All these histological evaluation procedures
were performed in a blind manner.
MEASUREMENT OF SYNOVIAL FLUID VOLUME
The synovial ﬂuid volume was calculated using the
Donnan equilibrium11,14,15. Synovial ﬂuid volume¼ total
calcium amount in the lavage of the joint cavity (g/joint)/cal-
cium concentration in the plasma (g/l). The calcium concen-
tration was determined using the arsenazo III complexion
method (Diagnostic calcium reagent, Sigma, MO, USA),
where 2 ml of the samples was chemically reacted with
200 ml of the calcium reagent for 5 min. Within 60 min after
the completion of this reaction, the calcium concentration
was spectrophotometrically determined at a wavelength of
600 nm.
PG DEGRADATION ANALYSIS
The amount of glycosaminoglycans (GAG) released from
the PG into the synovial ﬂuid was measured using the 1,9-
dimethylmethylene blue (DMB) colorimetric technique11,16.
The DMB solution was prepared by dissolving DMB
(16 mg, SigmaeAldrich, MO, USA) in 1 l total volume of
a solvent containing 95% ethanol (5 ml), formic acid
(3 ml), and 1 M NaOH (25.6 ml, pH 3.5) in distilled water.
The synovial ﬂuid of 50 ml was then mixed with 250 ml of
the DMB solution for 30 min, and the absorbance was
measured at a wavelength of 525 nm. The GAG concentra-
tions were then calculated by comparing the obtained
value with those of standard chondroitin sulfate solutions
(0e100 mg/ml of shark cartilage; Sigma, MO, USA). The
values of the standard solutions were 0, 3.13, 6.25, 12.5,
25 and 50 mg.
MEASUREMENT OF TOTAL PROTEIN LEVELS
The concentration of total protein in synovial ﬂuids sam-
ples was determined colorimetrically using Micro Bicincho-
ninic Acid (BCA) protein assay reagent (Sigma). The
synovial ﬂuids samples were incubated with Micro BCA
reagent (200 ml) in 96-well plate for 30 min at room temper-
ature. Bovine serum albumin (BSA) ranging 1e32 mg was
used as a standard. The absorbance was subsequently
measured at 562 nm using a microtiter plate reader.
MEASUREMENT OF PROSTAGLANDIN E2 (PGE2)
CONCENTRATION
The change in the PGE2 concentration within the synovial
ﬂuids after the induction of OA-like lesion and subsequent in-
jection with CG was assessed using a PGE2 enzyme
immunoassay (EIA) system (Amersham Pharmacia Biotech,
UK). The concentrations were then calculated by comparing
the obtained values with those of standard PGE2 solutions
(256 ng/ml of stock solution). The concentrations of the stan-
dard solutions were 2.5e320 pg/well (50e6400 pg/ml)11,17.
STATISTICAL ANALYSIS
The data were initially evaluated for normal distribution.
Statistical signiﬁcances among the groups were then
tested using Sigma Stat (SPSS Inc, USA) or a one-way
analysis of variance (ANOVA) and StudenteNewmane
Keuls test, depending on the normality of the data. The
signiﬁcances were further conﬁrmed by an unpairedStudent’s t test. Differences were considered signiﬁcant
when the P values were less then *P< 0.05, **P< 0.01,
or ***P< 0.001.
Results
HISTOLOGICAL EXAMINATIONS OF ARTICULAR CARTILAGE
The meniscal transection was done for anterior horn of
medial meniscus which showed serious lesion, although it
occurred both in medial and lateral surfaces. Gross assess-
ment of the articular cartilage following the partial menisec-
tomy revealed the extensive cartilage surface erosions with
exposure of subchondral bone in the OA-like group
[Fig. 2(B)], whereas normal, piroxicam-treated and CG-
treated groups have a normal appearance of the surface
[Fig. 2(A, C and D, respectively)]. The safranin-O staining
of PG in the cartilage showed that the PG was well pre-
served in the joints treated with CG or piroxicam yet not
in the joints treated with DMSO saline, where there was
a complete loss of PG [Fig. 3(A)]. The lesions at medial con-
dyle of each femur were scored according to Mankin’s grad-
ing system13. According to the Mankin’s grading system,
the OA-like cartilage (0.5% DMSO saline) had average
values of 11.67 1.15, while the CG-treated cartilage and
piroxicam-treated cartilage showed signiﬁcantly lower
values of 7.67 1.15 and 4.00 1.00, respectively
[P< 0.05, Fig. 3(B)].
MEASUREMENT OF SYNOVIAL FLUID VOLUME
After 2 weeks of treatment, the synovial ﬂuid volume
(Fig. 4) was signiﬁcantly elevated in the ACLMT-modiﬁed
joints of the 0.5% DMSO saline control group
(477.07 41.55 ml), yet clearly reduced in the CG-treated
(338.50 51.60 ml, P< 0.05) and piroxicam-treated (342.23
 20.15 ml, P< 0.001) groups. After 4 weeks, the CG- and
piroxicam-treated groups exhibited a 31.5% (409.43
74.78 ml, P< 0.05) and 26.1% (441.80 31.50 ml, P< 0.01)
decrease in the synovial ﬂuid volume, respectively, when
compared to the DMSO saline control group (597.60
17.13 ml).
AMOUNT OF TOTAL PROTEINS, GAG AND PGE2 IN THE
SYNOVIAL FLUID
The OA-like lesion resulted in a signiﬁcant accumulation
of total proteins, GAG, and PGE2 in the synovial ﬂuid from
the knee joints, when compared to the normal joints
(Fig. 5). As shown in Fig. 5(A), the amount of total proteins
in the synovial ﬂuid was signiﬁcantly increased along with
time by the OA-like lesion, which reduced clearly by the
treatment with CG or piroxicam both at 2 and 4 weeks.
The percent inhibition at 4 weeks for example was
about 48.6% (13.55 1.12 mg, P< 0.001) and 55.3%
(11.80 0.30 mg, P< 0.001) for CG-treated and piroxi-
cam-treated groups, respectively, when compared to the
DMSO saline control group (26.34 0.41 mg).
The major cause of cartilage degradation is the elevated
proteolytic activity that degrades aggrecan and type II
collagen. The loss of PG, determined through the increase
of GAG released into the synovial ﬂuid, was also signiﬁ-
cantly reduced in the CG-treated group when compared
to the DMSO saline control group [Fig. 5(B)]. At 4 weeks,
the GAG contents for CG- and piroxicam-treated groups
were 207.37 17.05 mg (63.7% reduction, P< 0.001) and
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tively, while that of the DMSO saline control group was
570.77 8.91 mg. At 2 weeks, the reduction in the GAG
content in the CG-treated group was not comparable to
that of the piroxicam-treated group, but showed statistically
signiﬁcant difference from that of the DMSO saline-treated
group (P< 0.05).
PGE2 is regarded as a marker of local inﬂammatory re-
sponses. The PGE2 level in the synovial ﬂuid was increased
by the OA-like lesion in the DMSO saline control group
(144.47 32.75 pg), which was inhibited only in the piroxi-
cam-treated group at 2 weeks (35.92 0.87 pg, P< 0.01)
[Fig. 5(C)]. The CG treatment showed no signiﬁcant reduc-
tion in the PGE2 level of OA-like group in the synovial ﬂuid
at 2 weeks and even induced it more at 4 weeks
(316.7 11.0 pg, P< 0.05).
Discussion
Our previous study revealed that the ethanol extracts of
AR or CG isolated from n-butanol soluble fractionates of
AR have a protective effect on the matrix degradation in
the HAase or IL-1b-induced chondrocytes and cartilage
explant cultures9. The present study demonstrated thatintra-articular injections of CG signiﬁcantly reduced the
pathologic changes resembling OA in a rabbit model by
the gross and histological observations of the cartilage
and the ﬂuid volume, protein content and GAG content in
the synovial ﬂuid. The order of magnitude of the biochemi-
cal and morphologic parameters was similar to those ob-
served in our previous studies11. We speculate that CG
could inhibit the degradation of cartilage directly and the
release of degraded molecules like GAG from damaged
tissues, which occurred in parallel with the reduction in
the volume of synovial ﬂuid.
The degradation of the articular cartilage and the subse-
quent release of the degraded molecules/fragments into the
synovial ﬂuid are typical pathologic changes of OA1. There-
fore, the analysis of the synovial ﬂuid from diseased joints is
useful to identify metabolic changes and abnormalities in
the articular cartilage. For example, the PG concentration
within the synovial ﬂuid can be used as a marker to estimate
the progress of OA19,20. Analysis of the joint ﬂuid, however,
offers some potential disadvantages. First, the synovial ﬂuid
is very difﬁcult to obtain. Second, the concentration of the
marker in the synovial ﬂuid depends on volume ﬂux through
the joints, which is not constant depending on the
disease or experimental conditions18. To diminish theseFig. 2. Macroscopic analysis of the cartilage from rabbit knees with OA-like lesion at 4 weeks. (A) Normal, (B) 0.5% DMSO saline (200 ml),
(C) piroxicam (100 mM), and (D) CG (100 mg/500 ml) treated group, respectively. The arrow indicates cartilage defect in 0.5% DMSO
saline-treated group.
1090 S. I. Choi et al.: Effect of an isoﬂavonoid on OAFig. 3. Protective effects of CG against cartilage degradation in the OA-like rabbit knees. (A) Representative sections of articular cartilage from
femoral condyle after 4 weeks of treatment period. Safranin-O staining was performed using the knee tissue sections from normal rabbits and
OA-like rabbits treated with 0.5% DMSO saline, piroxicam (100 mM), and CG (100 mg), respectively, after 4 weeks of administration. The loss
of safranin-O staining in the radial zone was signiﬁcantly reduced in the CG-treated group compared to the control group (100). (B) The
histological evaluation scores for the articular cartilage using the Mankin’s scoring system. The statistical difference between all experimental
groups was evaluated (n¼ 6/group). *P< 0.05, **P< 0.01, and ***P< 0.001.
1091Osteoarthritis and Cartilage Vol. 15, No. 9disadvantages anyhow, we obtained the synovial ﬂuid by
lavage of a synovial joint as described in Material and
methods and in the previous report11.
PGE2 has been shown to play an important role in
inﬂammatory arthritis21. However, it is uncertain whether
the local biomarkers of inﬂammation (PGE2, COX, and
NO) are predictors of the progression of OA22, although
the overproduction of PGE2 by COX-2 expression
in vivo has been reported for chronic inﬂammatory condi-
tions such as rheumatoid arthritis (RA)23. In this study,
the PGE2 level in the synovial ﬂuids was elevated by
OA-like lesion at 2 weeks, but was not increased at 4
weeks [Fig. 5(C)]. The CG injection was not so effective
in reducing the PGE2 level, when compared with the pir-
oxicam injection. This result suggests that the protective
effect of CG on the OA-like cartilage is probably due to
the direct inhibition of PG degradation. Interestingly in
this study, the CG injection at 4 weeks further induced the
synovial PGE2 level more than that by OA-like lesion alone.
It has been reported that antioxidants including inducible nitric
oxide synthase (iNOS) inhibitors could induce COX-2 activity
and the PGE2 production
24,25. Also, it is generally accepted
that some antioxidants have anti-inﬂammatory effects via
NF-kB inhibition pathway without inhibiting PGE2. For exam-
ple, vitamins E and C, PGs, N-acetylcysteine (NAC) and
some plant compounds inhibit nuclear factor kappa B (NF-kB)
dependent transcription by scavenging reactive oxygen spe-
cies (ROS) required for NF-kB activation26,27. Although CG
was shown to inhibit the COX-2 mRNA expression in a Raw
264.7 macrophage culture7, it is also well known that AR
has a strong anti-oxidative activity, thus possibly induces
COX-2 activity. Therefore, it could be speculative that the
overproduction of PGE2 by CG treatment was caused by
the induction of COX-2 activity via its anti-oxidative activity,
independent of its inhibitory effect on the COX-2 expression.
In summary, CG isolated from AR effectively protected
the knee joints of rabbits from OA-like changes in a rabbit
ACLMT model. To our knowledge, this is the ﬁrst report to
Fig. 4. Changes in the synovial ﬂuid volume. The synovial ﬂuid as-
pirated from the rabbits right after the ACLMT was used as the nor-
mal control. The ﬂuid aspirates were isolated after free-range
exercise following the ACLMT for 2 and 4 weeks from the OA-like
affected joints in the CG, piroxicam, and 0.5% DMSO saline groups
(n¼ 6/group). Values are shown as meanSD. The statistical dif-
ference was evaluated between the 0.5% DMSO saline group and
the treated groups. *P< 0.05, **P< 0.01, and ***P< 0.001.suggest that CG from AR could be a therapeutically effec-
tive agent for the alleviation of cartilage degradation in the
case of OA. Further studies are necessary to assess de-
tailed action mechanism of CG to regulate cartilage
Fig. 5. Changes in total protein, GAG and PGE2 contents in the sy-
novial ﬂuid. The amount of (A) total proteins, (B) GAG, and (C)
PGE2 was shown in the synovial ﬂuid before and after induction
of OA-like lesion, and after treatment with 200 ml 0.5% DMSO sa-
line, 100 mM piroxicam and 500 ml CG (100 mg), respectively
(n¼ 6/group). Values are shown as meanSD. The statistical dif-
ference was evaluated between the 0.5% DMSO saline group and
the treated groups. *P< 0.05, **P< 0.01, and ***P< 0.001.
1092 S. I. Choi et al.: Effect of an isoﬂavonoid on OAdegradation and inﬂammatory events including PGE2 and
NO syntheses.
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